Reviving Polymyxins: Achievements, Lessons and the Road Ahead

Advances in Experimental Medicine and Biology
Jian Li

Abstract

Antibiotic resistance has become the most significant threat to human health across the globe. Polymyxins are often used as the only available therapeutic option against Gram-negative 'superbugs', namely Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae. The limited pharmacological and clinical knowledge on the polymyxins in the old literature substantially limited optimizing their clinical use. The current chapter provides a general introduction to this first-ever polymyxin book which comprehensively reviews the significant progress over the last two decades in the chemistry, microbiology, pharmacology, clinical use and drug discovery of polymyxins. In particular, recent pharmacological results have led to the first scientifically-based dosing recommendations and facilitated the discovery of new-generation polymyxins. Future challenges in polymyxin research are highlighted, aiming at improving the clinical utility of this last-line defence.

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Related Papers

Advances in Experimental Medicine and Biology
David L Paterson, Robert A Bonomo
Diagnostic Microbiology and Infectious Disease
Phillip J BergenJian Li
Natural Product Reports
Tony VelkovJian Li
© 2021 Meta ULC. All rights reserved